Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
J Infect Dis. 2023 Oct 18;228(Suppl 6):S460-S464. doi: 10.1093/infdis/jiad267.
The coronavirus disease 2019 (COVID-19) pandemic demonstrated how rapidly vaccines and monoclonal antibodies (mAbs) could be deployed when the field is prepared to respond to a novel virus, serving as proof of concept that the prototype pathogen approach is feasible. This success was built upon decades of foundational research, including the characterization of protective antigens and coronavirus immunity leading to the development and validation of a generalizable vaccine approach for multiple coronaviruses. For other virus families of pandemic concern, the field is less prepared. The articles in this special issue have highlighted research gaps that need to be addressed to accelerate the development of effective vaccines and mAbs, to identify generalizable vaccine and mAb strategies, and to increase preparedness against other pandemic threats. Successful implementation of the prototype pathogen approach will require a systematic, multidisciplinary, coordinated approach with expertise and crosstalk among researchers of different virus families.
2019 年冠状病毒病(COVID-19)大流行表明,当该领域准备好应对新型病毒时,疫苗和单克隆抗体(mAbs)可以多么迅速地部署,这证明了原型病原体方法是可行的。这一成功建立在几十年的基础研究之上,包括保护性抗原的表征和冠状病毒免疫,从而为多种冠状病毒开发和验证了一种可推广的疫苗方法。对于其他具有大流行关注的病毒家族,该领域的准备工作还不够充分。本期特刊中的文章强调了需要解决的研究差距,以加速有效疫苗和 mAbs 的开发,确定可推广的疫苗和 mAb 策略,并提高对其他大流行威胁的准备。成功实施原型病原体方法将需要一种系统的、多学科的、协调的方法,需要不同病毒家族的研究人员具有专业知识和相互交流。